Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.79% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1626
DELISTED
Masimo
MASI
| $4.27M | 0.01% |
25,377
+10,377
| +69% | +$1.66M |
2025 Q1
1 quarter
|
|
1627
ESAB
ESAB
$4.13B
| $4.27M | 0.01% |
+35,400
| New | +$4.28M |
2025 Q2
0 quarters
|
|
1628
DELISTED
Vigil Neuroscience
VIGL
| $4.26M | 0.01% |
535,800
+316,400
| +144% | +$1.42M |
2024 Q1
5 quarters
|
|
1629
Jack Henry & Associates
JKHY
$10.5B
| $4.26M | 0.01% |
+23,619
| New | +$4.19M |
2025 Q2
0 quarters
|
|
1630
Simply Good Foods
SMPL
$923M
| $4.25M | 0.01% |
+134,500
| New | +$4.68M |
2025 Q2
0 quarters
|
|
1631
South Bow Corp
SOBO
$6.99B
| $4.25M | 0.01% |
163,880
+119,380
| +268% | +$3.04M |
2025 Q1
1 quarter
|
|
1632
Arhaus
ARHS
$1.35B
| $4.24M | 0.01% |
+489,500
| New | +$4.09M |
2025 Q2
0 quarters
|
|
1633
Veeco
VECO
$3.01B
| $4.24M | 0.01% |
208,810
+18,900
| +10% | +$373K |
2024 Q1
5 quarters
|
|
1634
J.M. Smucker
SJM
$12.8B
| $4.23M | 0.01% |
43,100
-12,679
| -23% | -$1.39M |
2019 Q2
24 quarters
|
|
1635
PetMed Express
PETS
$27.3M
| $4.23M | 0.01% |
1,273,869
-7,300
| -0.6% | -$26K |
2013 Q2
48 quarters
|
|
1636
CytomX Therapeutics
CTMX
$527M
| $4.23M | 0.01% |
1,862,200
+706,200
| +61% | +$1.14M |
2016 Q4
34 quarters
|
|
1637
Novavax
NVAX
$2.09B
| $4.21M | 0.01% |
667,647
+162,400
| +32% | +$1.08M |
2024 Q2
4 quarters
|
|
1638
Green Plains
GPRE
$1.02B
| $4.2M | 0.01% |
696,129
+341,000
| +96% | +$1.5M |
2022 Q4
10 quarters
|
|
1639
DELISTED
American Express Global Business Travel
GBTG
| $4.19M | 0.01% |
665,220
+151,600
| +30% | +$974K |
2023 Q4
6 quarters
|
|
1640
Vizsla Silver
VZLA
$1.24B
| $4.18M | 0.01% |
1,422,421
+447,521
| +46% | +$1.17M |
2023 Q1
9 quarters
|
|
1641
NBT Bancorp
NBTB
$2.62B
| $4.18M | 0.01% |
100,573
+62,734
| +166% | +$2.61M |
2024 Q1
5 quarters
|
|
|
ALEX
1642
DELISTED
Alexander & Baldwin
ALEX
| $4.15M | 0.01% |
232,831
-19,400
| -8% | -$338K |
2024 Q1
5 quarters
|
|
1643
iShares S&P 500 Growth ETF
IVW
$79.8B
| $4.15M | 0.01% |
+37,700
| New | +$3.73M |
2025 Q2
0 quarters
|
|
1644
Perella Weinberg Partners
PWP
$1.24B
| $4.15M | 0.01% |
213,600
-37,700
| -15% | -$666K |
2021 Q3
15 quarters
|
|
1645
Fox Factory Holding Corp
FOXF
$757M
| $4.14M | 0.01% |
159,693
+72,900
| +84% | +$1.71M |
2025 Q1
1 quarter
|
|
1646
Perma-Pipe International
PPIH
$254M
| $4.12M | 0.01% |
180,093
-7,900
| -4% | -$114K |
2013 Q2
48 quarters
|
|
1647
Concentra Group Holdings
CON
$4.79B
| $4.11M | 0.01% |
199,931
-42,200
| -17% | -$901K |
2024 Q3
3 quarters
|
|
1648
Evolv Technologies
EVLV
$782M
| $4.1M | 0.01% |
657,100
+441,300
| +204% | +$2.04M |
2025 Q1
1 quarter
|
|
1649
SGHC Ltd
SGHC
$5.7B
| $4.1M | 0.01% |
373,501
-485,800
| -57% | -$4.11M |
2023 Q4
6 quarters
|
|
1650
DELISTED
Semrush
SEMR
| $4.09M | 0.01% |
452,300
+104,600
| +30% | +$1.01M |
2024 Q2
4 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.